Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

KSQ-4279

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

KSQ Therap

Drug class:

USP1 inhibitor

Related drugs:

‹

›

BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	olaparib + KSQ-4279 Sensitive: D – Preclinical olaparib + KSQ-4279 Sensitive : D	olaparib + KSQ-4279 Sensitive: D – Preclinical olaparib + KSQ-4279 Sensitive : D
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	olaparib + KSQ-4279 Sensitive: D – Preclinical olaparib + KSQ-4279 Sensitive : D	olaparib + KSQ-4279 Sensitive: D – Preclinical olaparib + KSQ-4279 Sensitive : D
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + KSQ-4279 Sensitive: D – Preclinical olaparib + KSQ-4279 Sensitive : D	olaparib + KSQ-4279 Sensitive: D – Preclinical olaparib + KSQ-4279 Sensitive : D
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + KSQ-4279 Sensitive: D – Preclinical olaparib + KSQ-4279 Sensitive : D	olaparib + KSQ-4279 Sensitive: D – Preclinical olaparib + KSQ-4279 Sensitive : D